The Bull Case For American Superconductor (AMSC) Could Change Following Russell Index Exit And Backlog Surge

American Superconductor Corporation

American Superconductor Corporation

AMSC

0.00

  • In late June 2026, American Superconductor Corporation was removed from multiple Russell indices, including the Russell 3000E and Russell Microcap benchmarks, following the latest index reconstitution.
  • This index removal comes shortly after the company highlighted nearly US$100 million in fourth-quarter orders and a roughly 40% year-over-year increase in backlog to about US$280 million, underscoring a contrast between index status and operating momentum.
  • Now, we will examine how this combination of index removal and expanding backlog could influence American Superconductor's investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

American Superconductor Investment Narrative Recap

To own American Superconductor today, you have to believe its growing backlog in grid and wind projects will keep translating into healthy revenue and earnings, even as index-driven selling and shorter term volatility come and go. The recent Russell index removals may affect trading liquidity and sentiment, but they do not directly change the near term business catalyst, which is turning that roughly US$280 million backlog into cash flow, or the key risk around demand concentration in cyclical end markets.

The most relevant recent announcement here is management’s guidance for the June quarter, calling for revenue above US$85.0 million and net income above US$3.0 million. That outlook, coming on the heels of nearly US$100 million in fourth quarter orders, frames the index exit against a company still pointing to solid operating activity, but it also sharpens the focus on whether current utilization levels and mix can be sustained as projects in semiconductors, traditional energy, and renewables work through the pipeline.

Yet beneath the strong backlog, investors should be aware that the biggest risk right now is how exposed AMSC remains to lumpy, cyclical projects and what happens if just a few large orders...

American Superconductor's narrative projects $487.7 million revenue and $75.3 million earnings by 2029. This requires 17.7% yearly revenue growth and a $58.5 million earnings decrease from $133.8 million today.

Uncover how American Superconductor's forecasts yield a $65.33 fair value, a 57% upside to its current price.

Exploring Other Perspectives

AMSC 1-Year Stock Price Chart
AMSC 1-Year Stock Price Chart

Some of the lowest ranked analysts took a much tougher view, assuming earnings could fall toward about US$56 million on roughly US$462 million of revenue, and warning that long lead time, project based work might magnify any slowdown in orders, so it is worth weighing their caution against the more upbeat backlog story as you compare different viewpoints and decide how this latest index news might reshape expectations.

Explore 6 other fair value estimates on American Superconductor - why the stock might be worth as much as 57% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your American Superconductor research is our analysis highlighting 5 key rewards and 3 important warning signs that could impact your investment decision.
  • Our free American Superconductor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate American Superconductor's overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

  • Find 43 companies with promising cash flow potential yet trading below their fair value.
  • Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
  • AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.